
In the latest update from the DESTINY-Breast01 trial, the 26.5-month follow-up reveals the enduring effectiveness of trastuzumab deruxtecan (T-DXd) in treating HER2-positive metastatic breast cancer (mBC) after prior trastuzumab emtansine (T-DM1) therapy. Out of 184 patients, T-DXd demonstrated a 62.0% objective response rate, with a median overall survival of 29.1 months. Progression-free survival and duration of response were 19.4 months and 18.2 months, respectively. The findings reinforce T-DXd's sustained antitumor activity and consistent safety in extensively treated HER2-positive mBC patients.
Like
Save
Share